This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.
During the course of this presentation, certain non-GAAP financial information will be presented.
A reconciliation of those numbers to GAAP financial measures is available on the company's website atwww.aptar.com on the Investor's page (click onEvents & Presentations).
A Year of Resiliency
• Delivered on our promises to our customers, patients, consumers and partners
• Proud of our teams who faced the challenges presented throughout the year with unwavering strength and resilience
• Ensured the supply of our innovative solutions that dispense the medicines and consumer products needed by millions of people each day
• Well positioned to continue to invest and grow in 2021, and beyond
FY 2020 Recap
• Steady, long-term compounding growth story
• Achieved TSR of +102% over the past 5 years, ahead of our Peer Group and the S&P Midcap 4001
• Made strategic investments in our business in addition to M&A activity during the year to further strengthen our portfolio
• Diversified business model again proved to be resilient as we faced challenges in certain markets
• Achieved record cash flow from operations and record free cash flow
• Balance sheet remains in excellent condition and we are well positioned to continue to pursue strategic M&A opportunities
Initial Anticipated Pandemic Impact 2020
Sales GrowCtharbt yTiQtleuarter 2020
Q1
Q2
ReportedCoreQ3
Q4
1 Source: Standard & Poor's; Peer Group is defined in Aptar's Proxy Statement
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
AptarGroup Inc. published this content on 18 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2021 22:33:10 UTC.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.
APTARGROUP, INC. 
